Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Chief Business Officer | January 06, 2026 | January 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.81 · Expires 2036-01-05 | Direct | 300,000 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 300,000 · Balance 300,000 F1: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 8, 2026 16:05 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001193125-26-007667 · ownership.xml · derivative · entry 1 Wilson Perrin Megan · CIK 0002074091 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.